Published in Ann Neurol on December 01, 1994
Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol (2007) 2.17
Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol (2011) 1.73
Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromolecular Med (2009) 1.54
Brain magnetic resonance imaging and manganese concentrations in red blood cells of smelting workers: search for biomarkers of manganese exposure. Neurotoxicology (2006) 1.52
Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem (2008) 1.31
Effects of chronic manganese exposure on working memory in non-human primates. Brain Res (2008) 1.17
Paraparesis, hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis. Arch Dis Child (2000) 1.01
Acquired hepatocerebral degeneration. J Neurol (2009) 0.98
Novel bioimaging techniques of metals by laser ablation inductively coupled plasma mass spectrometry for diagnosis of fibrotic and cirrhotic liver disorders. PLoS One (2013) 0.95
Manganese accumulation in the brain: MR imaging. Neuroradiology (2007) 0.91
Blood and hair manganese concentrations in pregnant women from the infants' environmental health study (ISA) in Costa Rica. Environ Sci Technol (2014) 0.87
Air manganese levels and chronic liver disease mortality in North Carolina counties: an ecological study. Int J Environ Res Public Health (2012) 0.87
Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features. Int J Environ Res Public Health (2015) 0.86
Monitoring impacts of air pollution: PIXE analysis and histopathological modalities in evaluating relative risks of elemental contamination. Ecotoxicology (2014) 0.86
Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies. Surg Neurol Int (2015) 0.85
Manganese is toxic to spiral ganglion neurons and hair cells in vitro. Neurotoxicology (2010) 0.84
X-ray fluorescence imaging: a new tool for studying manganese neurotoxicity. PLoS One (2012) 0.84
Iron deficiency increases blood concentrations of neurotoxic metals in children. Korean J Pediatr (2014) 0.83
The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells. Neurotoxicology (2013) 0.82
Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle. J Intern Med (2013) 0.81
X-ray fluorescence imaging of the hippocampal formation after manganese exposure. Metallomics (2013) 0.80
Magnetic resonance imaging of brain in patients with cirrhotic and non-cirrhotic portal hypertension. Dig Dis Sci (2008) 0.78
Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. J Clin Invest (2017) 0.77
Identification of dopaminergic neurons of the substantia nigra pars compacta as a target of manganese accumulation. Metallomics (2015) 0.77
Hepatic encephalopathy: An approach to its multiple pathophysiological features. World J Hepatol (2012) 0.76
Disease-Toxicant Interactions in Parkinson's Disease Neuropathology. Neurochem Res (2016) 0.76
Chronic liver disease: relaxometry in the brain after liver transplantation. MAGMA (2001) 0.75
Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease. J Cell Mol Med (2015) 0.75
Mapping the basal ganglia alterations in children chronically exposed to manganese. Sci Rep (2017) 0.75
Redox dynamics of manganese as a mitochondrial life-death switch. Biochem Biophys Res Commun (2017) 0.75
Influence of iron metabolism on manganese transport and toxicity. Metallomics (2017) 0.75
Manganese deposition in the brain following parenteral manganese administration in association with radical operation for esophageal cancer: report of a case. Surg Today (1999) 0.75
Recent Updates on Acquired Hepatocerebral Degeneration. Tremor Other Hyperkinet Mov (N Y) (2017) 0.75
Manganese toxicity in critical care: Case report, literature review and recommendations for practice. J Intensive Care Soc (2015) 0.75
Dietary Manganese Promotes Staphylococcal Infection of the Heart. Cell Host Microbe (2017) 0.75
General and abdominal adiposity and risk of death in Europe. N Engl J Med (2008) 14.49
Randomized study comparing the "sniffing position" with simple head extension for laryngoscopic view in elective surgery patients. Anesthesiology (2001) 6.19
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med (2001) 6.07
Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology (2000) 2.90
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med (2001) 2.81
Repeated stress causes reversible impairments of spatial memory performance. Brain Res (1994) 2.55
Understanding cell death in Parkinson's disease. Ann Neurol (1998) 2.16
Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol (2009) 2.13
Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (1996) 2.05
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
Clinical predictors of abnormality disclosed by computed tomography after mild head trauma. Neurosurgery (1993) 2.03
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med (1999) 2.00
Interfacial activation of the lipase-procolipase complex by mixed micelles revealed by X-ray crystallography. Nature (1993) 2.00
Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci (2000) 1.97
Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem (1998) 1.95
Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol (1996) 1.87
Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord (2000) 1.78
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol (2000) 1.75
The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer (1996) 1.61
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med (1989) 1.59
Levodopa motor complications in Parkinson's disease. Trends Neurosci (2000) 1.58
DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis (2005) 1.54
Modafinil treatment of pramipexole-associated somnolence. Mov Disord (2000) 1.52
Sertraline for the treatment of depression in Parkinson's disease. Mov Disord (1997) 1.50
Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia (1999) 1.50
Use of dietary supplements in the European Prospective Investigation into Cancer and Nutrition calibration study. Eur J Clin Nutr (2009) 1.49
Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery (1995) 1.49
Low section of the rectum during laparoscopic total mesorectal excision using the Contour device. Technical report. Surg Endosc (2006) 1.48
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord (1993) 1.48
QTL mapping of grain quality traits from the interspecific cross Oryza sativa x O. glaberrima. Theor Appl Genet (2004) 1.48
The core assessment program for intracerebral transplantation. Mov Disord (1995) 1.47
Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol (1998) 1.45
Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol (1995) 1.44
Postthymectomy wasting associated with autoimmune phenomena. I. Antiglobulin-positive anemia in A and C57BL-6 Ks mice. J Exp Med (1967) 1.44
Low IgG2 and polysaccharide response in a T cell receptor expression defect. Eur J Immunol (1990) 1.43
Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet (2004) 1.42
Folk diseases among urban Mexican-Americans. Etiology, symptoms, and treatment. JAMA (1966) 1.41
Pulmonary arterial hypertension and cor pulmonale associated with chronic domestic woodsmoke inhalation. Chest (1993) 1.41
Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta (1999) 1.41
One hundred consecutive advanced breast biopsy instrumentation procedures: complications, costs, and outcome. Ann Surg Oncol (1999) 1.39
Adhesion molecules: clinical implications. Surgery (2000) 1.39
Levodopa: why the controversy? Lancet (2002) 1.39
Progressive dementia and gait disorder in a 78 year old woman. J Neurol Neurosurg Psychiatry (2000) 1.39
High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol (1997) 1.36
The development and function of gamma delta T cells. Immunol Today (1990) 1.33
Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature (1990) 1.33
Balloon-expandable stent repair of severe coarctation of aorta. Am Heart J (1995) 1.29
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol (1999) 1.26
Restraint stress reversibly enhances spatial memory performance. Physiol Behav (1996) 1.25
The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood (2001) 1.24
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol (1999) 1.22
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol (1998) 1.22
The immunologic competence of mouse thymus cells measured by the graft vs. host spleen assay. J Immunol (1966) 1.21
Functionally distinct subsets of human gamma/delta T cells. Eur J Immunol (1991) 1.21
Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol (1996) 1.21
Pneumonia due to Bordetella bronchiseptica in a patient with AIDS. Rev Infect Dis (1991) 1.21
Analysis of genetic variability and mapping of point mutations in influenza virus by the RNase A mismatch cleavage method. Proc Natl Acad Sci U S A (1988) 1.21
Laparoscopic feeding jejunostomy: also a simple technique. Surg Endosc (1993) 1.21
Prolongation of intestinal allograft survival without immunosuppressive drug therapy. Transplantation of small bowel allografts. J Surg Res (1983) 1.20
Interleukin 2 promotes growth and cytolytic activity in human T3+4-8- thymocytes. Proc Natl Acad Sci U S A (1985) 1.19
Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol (2000) 1.18
Mapping of genes controlling aluminum tolerance in rice: comparison of different genetic backgrounds. Mol Genet Genomics (2002) 1.18
The multicentre south European study 'Helios'. I: Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer (1996) 1.17
The evolution and origin of motor complications in Parkinson's disease. Neurology (2000) 1.15
A suggested mechanism for T lymphocyte activation: implications on the acquisition of functional reactivities. Immunol Rev (1980) 1.15
Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res (1992) 1.14
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol (1995) 1.13
A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol (1998) 1.11
Small bowel allografts. Sequence of histologic changes in acute and chronic rejection. Am J Surg (1986) 1.11
Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr (2006) 1.10
Inducible binding of cyclic adenosine 3',5'-monophosphate (cAMP)-responsive element binding protein (CREB) to a cAMP-responsive promoter in vivo. Mol Endocrinol (1999) 1.10
Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg (2001) 1.10
Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (Berl) (2001) 1.08
Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest (1984) 1.08
Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer (2006) 1.08
Dynamics of indigenous yeast populations during spontaneous fermentation of wines from Mendoza, Argentina. Int J Food Microbiol (2005) 1.08
Occupation and parkinsonism in three movement disorders clinics. Neurology (2005) 1.08
Dynamics of Fusarium solani cutinase investigated through structural comparison among different crystal forms of its variants. Proteins (1996) 1.07
Immunohistochemical localization and distribution of torsinA in normal human and rat brain. Brain Res (2000) 1.07
Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks. Antimicrob Agents Chemother (1990) 1.07
Thymic stroma is required for the development of human T cell lineages in vitro. Int Immunol (1989) 1.07
Microphthalmos with cyst: clinical presentations and computed tomographic findings. J Pediatr Ophthalmol Strabismus (1985) 1.07
Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol (1996) 1.06
Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg (2004) 1.06
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol (1999) 1.06
Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol (2007) 1.05
Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther (1989) 1.05
Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci (1996) 1.04
Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol (1996) 1.04
Anatomy of the gonadal veins: a reappraisal. Surgery (1991) 1.04
VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci (2006) 1.03
Nerve root prolapse into a spinal arachnoid cyst--an unusual cause of radiculopathy. Clin Neurol Neurosurg (2009) 1.03
[Tuberculosis and diabetes mellitus: a longitudinal-retrospective study in a teaching hospital]. Rev Med Chil (1989) 1.03